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A B S T R A C T   
Recent advances have driven the development of stem cell-derived, self-organizing, three-dimensional miniature 
organs, termed organoids, which mimic different eye tissues including the retina, cornea, and lens. Organoids 
and engineered microfluidic organ-on-chips (organ chips) are transformative technologies that show promise in 
simulating the architectural and functional complexity of native organs. Accordingly, they enable exploration of 
facets of human disease and development not accurately recapitulated by animal models. Together, these 
technologies will increase our understanding of the basic physiology of different eye structures, enable us to 
interrogate unknown aspects of ophthalmic disease pathogenesis, and serve as clinically-relevant surrogates for 
the evaluation of ocular therapeutics. Both the burden and prevalence of monogenic and multifactorial 
ophthalmic diseases, which can cause visual impairment or blindness, in the human population warrants a 
paradigm shift towards organoids and organ chips that can provide sensitive, quantitative, and scalable 
phenotypic assays. In this article, we review the current situation of organoids and organ chips in ophthalmology 
and discuss how they can be leveraged for translational applications.   
Introduction 
Loss of vision severely affects the quality of life and is one of the most 
feared health conditions in society. The demand for basic research on 
ophthalmic diseases is rising due to the increasing world population and 
the increase in life expectancy and subsequent rise in the number of 
cases of ophthalmic diseases such as corneal dystrophy (e.g., Fuchs’), 
dry eye disease, Sjögren’s syndrome, retinitis pigmentosa (RP) and 
retinoblastoma. Previously, experimental studies have been performed 
in vivo on animal models (from Drosophila and zebrafish to rodents and 
large mammals) or in vitro cell culture models [1–3]. These models have 
contributed to ophthalmology in many ways, including their role in 
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finding basic functional characteristics at the cellular level, modeling 
eye development, disease pathogenesis, therapy development, and drug 
screening [4–9]. However, these studies can suffer from limited clinical 
translatability, for example, due to species differences in the tropism of 
viral vectors or the transcriptome for both protein-coding and 
non-coding transcripts [10–12]. The commonly used in vitro models 
often fail to reproduce organ-level functionality, which is needed for 
realistic disease modeling. Therefore, more representative models of 
human eye tissues are required [13]. 
In response to this need, two new technologies have been recently 
developed: organoids and organ-on-chips (organ chips) [13,14]. Orga-
noids are stem cell-derived, three-dimensional assemblies that consist of 
organ-specific cell types that self-organize through cell sorting and 
spatially restricted lineage commitment, thus mimicking the architec-
tural and functional complexity of native organs [15]. Organoids are 
derived from embryonic stem cells (ESCs), induced pluripotent stem 
cells (iPSCs), or organ-restricted adult stem cells (aSCs). During stem cell 
differentiation, temporal manipulation of the in vitro microenvironment 
through supplementation with exogenous components such as growth 
factors, small molecules, and extracellular matrix (ECM) substrates can 
simulate conditions of the fetal microenvironment, and improve orga-
noid differentiation and maturation [15]. Another evolving model is 
organ chip technology, which combines the uses of microfluidic tech-
nology, biomaterials, and cell culture techniques to model human-like 
organs on a micro-scale. Organ chips are microchips designed to reca-
pitulate the microarchitecture and function of living human organs. 
Commonly, organ chips are transparent, contain varying hollow 
microfluidic channels and cell compartments which can be lined by 
living human organ-specific cells. External artificial forces can be 
applied to mimic the physical microenvironment of the living organs. 
Organoids and organ chips have been developed to model many organs, 
including the gut, liver, kidney, brain, and more recently, eye structures 
including the retina, cornea, and lens [16]. In this article, we discuss the 
use of organoids and organ chips in ophthalmology. We review the use 
of these techniques to study eye development and physiology, disease 
mechanisms, and the development of diagnostic assays and therapeutics 
for personalized medicine. 
Cornea 
The cornea is the transparent outermost layer of the eye that is 
responsible for focusing most of the incoming light and is thus essential 
for vision. Over the last decades, efforts have been made to create in vitro 
corneal models. In 1993 Minami et al. succeeded in reconstructing the 
three layers of the cornea (endothelium, stroma, and epithelium) from 
cells isolated from bovine cornea tissues [17]. The three layers were 
engineered sequentially on top of each other, with the epithelial layer 
interfacing a liquid/air matrix. A similar approach was employed to 
develop the 3-dimensional corneal model derived from human cells by 
Germain et al. that reconstructed corneas by culturing epithelial cells on 
collagen gels containing fibroblasts [18]. Griffith et al. fabricated a 
human corneal model employing human corneal cell lines. They found 
that their model resembled the human cornea in morphology, trans-
parency, and histology. The model responded to both stromal swelling 
and corneal wound healing to a degree similar to post-mortem cornea 
[19]. The efforts to develop the 3D cornea model entered a new phase 
with the introduction of organoid technology and chip-based modeling. 
In what follows, we discuss corneal organoids and cornea chips, and 
then describe their applications to drug studies. 
Corneal organoids 
Corneal organoids are 3D cornea models designed to be suitable for 
developmental studies, modeling of some cornea disorders, and possibly 
organ replacement purposes [20]. Organoids are generated from em-
bryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) that 
differentiate into various cornea cells [21–24]. 
In a breakthrough study, Foster et al. used human iPSCs to develop 
corneal organoids. These organoids contained three cell types of the 
cornea - epithelium, stromal keratocytes, and the endothelium. These 
structural features were characterized using immunofluorescence 
staining for epithelial markers (KRT3, KRT14, and p63), stromal kera-
tocytes (CD34), and endothelial markers (COL8A1, F11R, S100A4). In 
addition, these organoids consisted of extracellular matrix collagens and 
proteoglycan core proteins which are essential components of the stro-
mal matrix. TEM and immunofluorescence staining showed different 
matrix proteins and organized protein fibrils in different layers of the 
organoids. While the outer layers contained perlecan and collagen type 
VIII, the deeper layers stained for stromal proteins LUM and KERA, 
Collagen types I and V [25]. 
Shortly after the development of corneal organoids by Foster et al. a 
new protocol was developed by Susaimanickam et al. which generated, 
using a simpler and more efficient culture method, more complex 3D 
corneal organoids and even, in rare cases, whole eyeball-like structures. 
In this protocol, either human ESCs or human iPSCs are cultured in situ 
in retinal differentiation medium (RDM), with the absence of noggin. 
After four weeks in culture, the stem cells had differentiated in eye field 
primordial clusters (EFPs). They found that continued in situ differen-
tiation of these EFPs in RDM led to the formation of lens epithelial 
clusters, ocular surface epithelium, and optic cups. Interestingly, they 
found that in rare cases the EFPs gave rise to 3D miniature eyeballs, 
including an anterior transparent cornea primordium surrounded by the 
neuroretinal cup. At two weeks of suspension culture, the EFPs gave rise 
to both retinal and corneal primordia. At this point, the corneal 
primordia regions were lifted and cultured in the corneal differentiation 
medium (CDM) for further maturation. Six to eight weeks after culturing 
the corneal primordia gave rise to minicorneas. Subsequent examination 
of these minicorneas showed prevalent corneal morphological structures 
and expressed cornea-specific markers [26]. 
These corneal organoids open up possibilities for multiple down-
stream applications that are unattainable using current in vitro culture 
systems. 
Cornea chips 
Engineering cornea mimics on chips is still at its infancy. A few steps 
have been taken towards modeling cornea; despite their simplicity, 
current cornea chips are already able to recapitulate certain disease 
features. Puleo et al. made the first attempt to culture cornea cells in 
microfluidic devices in 2009 [27]. They succeeded in developing a 
bilayer structure containing a corneal epithelial layer and a layer of 
stromal cells on a collagen vitrigel substrate. The model was then used to 
measure transepithelial permeability. Nearly a decade later, Bennet 
et al. developed a cornea chip that included epithelial layers, basement 
membrane, and Bowmen’s membrane, and importantly, they simulated 
tear flow dynamics in their microfluidic device [28]. They used 
immortalized human corneal epithelial cells (hTCEpi) and cultured 
them on a Polydimethylsiloxane (PDMS) membrane. They found that 
cells seeded on a fibronectin-coated membrane were more viable 
compared to uncoated or collagen-coated membranes. The permeability 
of the epithelium underflow closely resembled in vivo conditions. 
A significant breakthrough in the development of an ocular surface 
chip was the chip development by Seo et al. that integrated both cornea 
and conjunctiva structures in one platform and interfaced them with a 
blinking eyelid [14]. They developed a dome-shaped scaffold with a 
perfusion system and an eyelid mimic that is actuated to slide on the 
scaffold. The cornea mimic included epithelial cells with primary human 
keratocytes embedded in a hydrogel to mimic the stroma. Using a 3D 
patterning approach, concentric patterns of the conjunctiva (including 
epithelial and goblet cells) and cornea structures were fabricated. The 
structure, however, lacked vasculature and immune cells that are pre-
sent in the conjunctiva in vivo. 
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The ocular surface chip developed by Seo et al. recapitulated 
important anatomical and physiological properties of human counter-
parts [14]. Stratified epithelium in this device is composed of 7–8 layers 
of epithelial cells (similar to in vivo conditions) as well as a layer of cells 
expressing basal cell-specific marker (p63). Similarly, the engineered 
conjunctiva contained multiple epithelial layers and showed the 
expression of key biochemical markers. Importantly, the tissue could 
produce mucin proteins. An essential aspect of this design is that the 
model incorporates key mechanical processes including blinking with 
physiological frequencies (e.g., 0.2 Hz) as well as tear film dynamics. 
The tear secretion rate of the device was properly tuned to its natural 
values, and a drainage system for tear excess was designed. This ensured 
the maintenance of a very thin and uniform tear film of approximately 6 
μm thickness (within the range of in vivo values), as shown by optical 
coherence tomography. The blinking process was shown to be nonin-
vasive to the ocular surface and did not lead to scarring. The mechanical 
shear was shown to promote cellular differentiation in the epithelial 
layer, indicating that the eyelid is more than just a “lid” and the me-
chanical forces are sensed and responded to by the cellular biochemical 
network. 
Ocular surface chips remained to be adapted and used as disease 
models. The only major development in this direction was the engi-
neering of a Dry Eye Disease (DED) model on the platform developed by 
Seo et al. [14]. By reducing the frequencies of blinking from 12 to 6 
times per minute and adjusting the humidity of the environment allows 
for the simulation of an evaporative DED model. Reduced blinking fre-
quency leads to changes in tear osmolality and film instability, as shown 
by break-up time estimation. Importantly, these DED related biome-
chanical changes led to cellular changes seen in DED in vivo. For 
example, inflammatory cytokines such as interleukin 1β, TNFα, and 
matrix metalloproteinase (MMP)-9 were overexpressed upon the 
reduction of blinking frequency in the chip. Overall, this 
proof-of-concept study demonstrates that the chip model can capture the 
mechanical and biochemical features of DED (Fig. 1). These results are 
highly promising and set the stage for the development of chip-based 
models for other ocular surface diseases. For this aim, one may have 
to incorporate additional complexities e.g. the immune system and 
vasculature. 
Applications to drug studies 
Cornea chips have been used to study pharmacokinetics and pre-
clinical drug evaluation Bennet et al. performed a drug study on their 
model with Pred Forte (Prednisolone 1%) and Zaditor (Ketotifen) to 
assess the functionality of their model in drug permeability [28]. They 
found that the pulsatile tear flow had the most similarity to the human 
eye than the continuous flow or static condition [28]. Their findings 
were correlated with the formulation of the drug and mode of the action 
of the chip (static or with the flow) so that it would be a representative 
model of the human cornea in vitro [28]. Unfortunately, pharmacolog-
ical immunomodulation of the ocular surface cannot be accurately 
mimicked using current chip designs, as these designs lack the immune 
system. However, nonimmunological processes can be drugged effec-
tively in chip models of ocular surface inflammatory diseases. An 
example of such a study is the analysis conducted on the DED model of 
Seo et al. [14]. They exposed the DED model to endogenous lubricin to 
assess whether the findings of this in vitro model are comparable with 
clinical outcomes. The results not only showed increased break-up time 
and decreased area of the film tear rupture but also changed corneal 
fluorescein staining resembling what was found in the clinical trials. 
This analysis shows the values of cornea chips, as these “clinical” mea-
surements are now possible at the preclinical stages of drug analysis, 
Fig. 1. Dry eye disease chip. a) Evaporation induced break-up of the tear film and increase of tear osmolarity together lead to a loss of homeostasis. b) Absorption of tears into 
the Schirmer strips in the healthy and DED models. Tear absorption is visualized by the smearing of the blue ink within the strips. c) Tear osmolarity in the DED (closed triangle) 
and the healthy (closed circle) models. Human clinical data of osmolarity are from healthy (open circle) and DED subjects (open triangle). d) Keratographs showing concentric 
rings projected on the human ocular surface (top) and the engineered ocular surface (bottom). e) Representative images of projected ring patterns on the engineered ocular 
surface of the healthy (top row) and the DED (bottom row) groups captured at t = 0 s (left column) and t = 10 s (right column). f) Spatial mapping of tear film break-up time in 
the normal (top) and the DED (bottom) models. Different colors in the representative circular heat maps indicate different tear break-up times. g) Fluorescein staining of the eye 
model and human subjects. h) Concentrations of inflammatory mediators (IL-8, TNF-α, IL-1β, and MMP-9) in the normal (circle) and the DED (triangle) groups plotted against 
the duration of culture. The figure is taken from Jeongyun Seo et al. with permission [14]. (For interpretation of the references to color in this figure legend, the reader is 
referred to the Web version of this article.) 
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thanks to the chip technology. Furthermore, the DED model was used to 
discover the therapeutic effect of lubricin at the molecular scale. Con-
centration profiles of inflammatory factors such as toll-like receptor-4 
(TLR-4) of IL-8, TNF-α, IL-1β, and MMP-9 can be measured in the tear 
film. The DED model showed a marked decrease in inflammatory 
markers upon lubricin administration, in agreement with the findings of 
clinical trials. 
One important issue in drug assays on cornea chips relates to drug 
permeation and accessibility to ocular surface layers. Bai et al. created a 
cornea chip model to determine dextran diffusion permeability across 
the corneal barriers [29]. They used dextran with several distinct mo-
lecular weights ranging from 10 kDa to 70 kDa to simulate drug diffu-
sion across cornea layers and to measure permeability. They found that 
epithelium is a major determinant of drug transportation rates. Future 
studies are needed to investigate the translational value of these drug 
transport data. This is because the proof-of-concept analysis by Bai et al. 
was based on mouse cornea cells and did not include the cellular 
complexity of human cornea and its collagen content precisely. 
Lacrimal glands 
The lacrimal glands (LGs) secret tear fluids, which contain water, 
electrolytes, and various secreted substances to the ocular surface. Tears 
play physiologically important roles in maintaining the homeostatic 
environment on the ocular surface epithelium, such as lid lubrication, 
hydration, antimicrobial activity, and protection of the ocular surface 
epithelium. Tear shortage from LGs, which is induced by aging and 
various pathological conditions, causes dry eye disease (DED). DED is 
defined at TFOS/DEWS II as a multifactorial disease of the ocular surface 
characterized by a loss of homeostasis of the tear film, and accompanied 
by ocular symptoms, in which tear film instability and hyperosmolarity, 
ocular surface inflammation and damage, and neurosensory abnormal-
ities play etiological roles. Recently, a therapeutic concept of functional 
lacrimal gland restoration using regenerative medicine, including 
organoids from pluripotent stem cells, has emerged as a possible way to 
treat severe DED. 
Lacrimal gland organoids 
One of the challenges for the lacrimal gland regeneration is to 
reconstruct secretory gland structures and coordinated organ systems 
with peripheral tissues, such as nerves and blood vessels, because 
organogenesis requires a complex process involving tissue self- 
organization, cell-cell interactions, signaling with various molecules 
for correct cell differentiation to form organs [30,31]. A method in 
biotechnology based on knowledge from developmental biology for 3D 
stem cell manipulation in vitro, which is designated to mimic organ germ 
formation during organogenesis, allowed us to generate bioengineered 
organ germs, including teeth, hair follicle, and salivary glands and LGs, 
by using embryo-derived organ inductive stem cells (Fig. 2a) [32–37]. 
The bioengineered lacrimal gland germs, which were generated with 
compartmented cells of epithelial and mesenchymal stem cells isolated 
from mouse lacrimal gland germs in a collagen gel, initiate develop-
mental processes involving the self-organization and multiple cellular 
assembling to form tubule-alveolar structures in vitro (Fig. 2b). The 
bioengineered lacrimal gland germs achieve mature lacrimal gland 
structures and recapitulate their connection with peripheral tissues and 
innervation for fully tear-secretion functions after orthotopic engraft-
ment in vivo (Fig. 2c and d). As reported in the bioengineered teeth 
regeneration study, the development of a method to mature the bio-
engineered lacrimal gland germs in vitro, which can immediately func-
tion the bioengineered organs in vivo, will contribute to lead future 
organ replacement therapy for DED [34]. These studies have demon-
strated that the functional bioengineered lacrimal glands for organ 
replacement therapy can be achieved by reproduction of the develop-
mental process of LGs in organogenesis. 
An organoid as a partially functional mini-organ can be generated by 
using specific developmental gene expression and cytokine signaling, 
which induce self-organized body patterning and subsequent organ- 
forming field from pluripotent stem cells [38–43]. Recently, fully 
Fig. 2. Development of the bioengineered lacrimal glands in vitro and in vivo. (a) Functional lacrimal gland regeneration using mouse embryo-derived organ-inductive stem cells 
in the 3D culture environment. (b) Organogenesis of the bioengineered lacrimal glands with branching morphogenesis in vitro (left and center panels) and an image of HE 
staining of the bioengineered lacrimal gland (right panel). scale bar, 200 μm. (c) Functional lacrimal gland replacement after orthotopic transplantation in vivo. Arrowhead 
shows the connection between the host lacrimal excretory duct and the bioengineered lacrimal gland. Scale bar, 500 μm. (d) The bioengineered lacrimal glands developed with 
full functionality. Ds-red expressing epithelium achieved acini and duct structures. FITC gelatin (green), which was injected from the host lacrimal excretory duct, reached to the 
bioengineered lacrimal gland. Arrowhead shows the connection between the host lacrimal excretory duct and the bioengineered lacrimal gland. Scale bar, 200 μm. The figures 
were reprinted from Refs. [48]. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) 
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functional salivary glands from mouse ES cells have been generated 
through the induction of organ-forming field (the oral ectoderm; for the 
salivary glands) with the expression of specific genes for salivary gland 
development [44]. In the field of the lacrimal gland regeneration, a set 
of transcription factors, which plays a role in the lacrimal gland devel-
opment, has been clarified to induce the organ-forming field and 
signaling for the lacrimal gland organoids [45,46]. As well as the pos-
sibility of tissue stem cell injection therapy reported previously [47], the 
further development of this method of organoid technology for LGs will 
contribute to the realization of lacrimal gland regenerative medicine. 
Lacrimal gland chips 
Various innovations in bioengineering have been applied to regen-
erate functional organs to treat or modeling diseases. For example, 
artificial regulation of tear secretion from LGs by stimulating neural 
pathways using medical devices has been proposed [49]. To generate 
complex secretory gland structure, previous reports have used biohybrid 
materials, such as a decellularized scaffold, for a successful 3D recon-
struction of LG [50,51]. Other studies have reported the in vitro models 
of several components of the ocular surface, such as conjunctival tissues 
and lacrimal gland epithelium [52], individually [53]. The 3D culture 
environment, including microgravity cell culture and Matrigel culture 
methods, has been a key to investigate the lacrimal gland function and 
DED [54–56]. A tissue engineering technology for reconstruction of a 
complex 3D organ system (LGs-tear film-ocular surface) has been 
attempted to build up in vitro disease modeling of DED [57]. These 
studies have indicated that it is effective to create functional tissue 
mimics, which use a co-culture system of various tissues of tear 
film-ocular surface system including the lacrimal gland spheroids and 
conjunctival epithelium, as a model for DED and therapeutic evaluation. 
The next-generation research of the lacrimal gland regenerative medi-
cine using organoids and organ chips is now expanding as a viable model 
based on recent exponential advances in developmental biology, stem 
cell biology, and tissue engineering technology. 
Retina 
Retinal organoids 
The first retinal organoids (ROs) were made from mouse (m)ESCs 
[13,58]. The Sasai laboratory found that the development of the optic 
cup is a self-directed process and does not rely on influence from 
external structures. Their model had the six major types of neurons and 
one glial cell type of the retina and could recapitulate many aspects of 
retinal function, including morphogenetic movements, interkinetic nu-
clear migration, and apical-basal polarity [13,58]. Although their model 
was not perfect in recapitulating all facets of the adult mouse retina, 
including a low percentage of cone photoreceptors, it was a milestone in 
generating more advanced retinal models that recapitulated in vivo 
characteristics of the mouse retina. Further optimization of their pro-
tocol enabled the generation of human (h)ESC-derived ROs for the first 
time (Nakano et al.) [40]. Compared to the stem cell-derived RO mouse 
model, the retina derived by this method had longer culture time, which 
is due to the inherent differences in gestational periods between species. 
The methodology used was based entirely on a 3D approach relying on 
extrinsic modulation of cell signaling pathways. Starting from a single 
cell suspension of hESCs, the cells are seeded in equal numbers in 
V-bottomed wells of a 96-well plate and undergo quick aggregation to 
form embryoid bodies (EB). EBs undergo neural induction and form 
optic vesicles, which are subsequently kept in suspension culture for 
maturation to laminated ROs [40]. The main alternative to this meth-
odology, popularized by Zhong et al., requires far less extrinsic modu-
lation of cell signaling pathways and proceeds in a mostly self-directed 
process. Here, hiPSCs are grown to near confluence and made into small 
floating aggregates, either chemically or mechanically, in suspension to 
form EBs which undergo neural induction. Subsequent plating of EBs 
allows for the formation of the retinal neuroepithelium, which can be 
individually dissected from the bottom of the well, or alternatively, the 
whole contents of the well can be lifted after mechanically scoring the 
well in a grid pattern. This is followed by the sorting of ROs for long term 
suspension culture were they undergo lamination and maturation [59, 
60]. An alternative to this approach is to let hiPSCs grow to confluence 
and, instead of generating small floating aggregates, remain as adherent 
cultures. Removal of FGF2 from the culture medium initiates sponta-
neous differentiation which is followed by the promotion of neural in-
duction and retinal neuroepithelium formation [61,62]. The 
methodology by Zhong et al. was the first to show fully laminated 3D 
iPSC-derived retinal tissue which also yielded more developed 
outer-segment structures that responded to light stimuli [59]. A third 
methodology by Lowe et al. used small aggregates of hESCs embedded in 
Matrigel to form single-lumen epithelial cysts that subsequently adhere 
to the culture surface forming colonies of retinal progenitors. Dispase 
treatment promoted lifting of these colonies, which in floating suspen-
sion culture formed laminated and maturating retinal organoids [63]. 
The use of hESCs and hiPSCs has been successfully implemented using 
all three methodologies, and continued modifications and optimizations 
are being implemented [40,59,60,64–68]. The retinal architecture of the 
human fetal retina is recapitulated in hiPSC retinal organoids (Fig. 3). 
Organoids are useful for understanding the developmental physi-
ology of the retina and its underlying transcriptomic mechanisms. Here, 
we provide some examples of RO implementation for these purposes. 
Previously, an essential role of thyroid hormone signaling on cone cell 
viability and opsin expression has been established. However, the exact 
mechanism of cone cell differentiation was not known [69]. Retinal 
organoids have been implemented to further elucidate this mechanism. 
Eldred et al. found that the retina plays an active role in specifying S or 
L/M cone subtypes through the temporal expression of thyroid hormone 
degrading and activating proteins. In early retinal development, thyroid 
hormone levels are kept low which initiates differentiation to S cones, 
later in development thyroid hormone levels rise to specify L and M cone 
cells [70]. 
The organoid models can be used for studying the effect of different 
genes in eye formation and neuroretina differentiation. Takata et al. 
studied the effect of R-spondin 2 (Rspo2) and Sine oculis-related ho-
meobox 3 (Six3) genes [71]. They used Six3− /− miPSC-derived and Six3 
conditional knockout (CKO) mESC-derived organoids, finding that 
Six3-mediated suppression of Rspo2 is necessary for neuroretina differ-
entiation and optic vesicle morphogenesis [71]. 
Capowski et al. studied the expression pattern of microphthalmia- 
associated transcription factor (MITF) during differentiation in their 
hESC-derived optic vesicle model. MITF is a vital regulator of pigmented 
cell survival and differentiation. They found that in addition to the role 
of MITF in retinal pigment epithelium (RPE) development, it is also 
crucial for early optic vesicle cell proliferation [73]. Quinn et al. used 
hiPSC-derived ROs and human fetal retina to investigate the onset of 
expression of CRB1 (Crumbs homolog-1) and CRB2 during development 
and early maturation of the retina [72]. Mutations in CRB1 are associ-
ated with a spectrum of retinal dystrophies including RP type 12 and 
LCA type 8 [74–78]. They found that during the first trimester, CRB2 is 
the predominant CRB family member. In contrast, the onset of expres-
sion of the canonical CRB1 protein at the subapical region coincides with 
the maturation of the retina during the second trimester. This pattern of 
CRB1 and CRB2 expression was recapitulated in ROs [72]. To verify that 
retinal ganglion cells (RGCs) can be identified by the expression of 
specific surface antigens. Aparicio et al. compared surface antigen 
expression patterns in the human fetal retina and hESC-derived ROs. 
They found that CD184 and CD171 were expressed in RGCs from both 
tissues and that early post-mitotic RGCs express high levels of CD184 
while CD171 expression is found in maturating RGCs. These cell surface 
markers could then be used to purify the RGC population using flow 
cytometry [79]. RGCs derived from ROs can be used as an effective 
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platform to investigate RGC development, organization, and neurite 
outgrowth [80]. 
ROs have been used to profile the dynamic transcriptional landscape 
of retina from early progenitors to differentiated retinal cell types 
[81–83]. These transcriptomic data have been achieved by using 
different reporter lines, each assessing a specific type of cell in the 
human retina. Hereby nine different clusters of cells have been observed 
during the differentiation of ROs. It has been found that mitotic cells and 
RGCs decrease over time, rod and cones are formed afterward, and 
Müller glia increases towards day 200 [84]. Neural retina leucine zipper 
(NRL) is a gene that has a critical role in rod photoreceptor formation, 
and patients with NRL mutations exhibit rod degeneration enhanced 
S-cone syndrome and RP. ROs of null NRL models have also been 
developed to study the cone photoreceptor development in 
human-derived ROs [85]. These models can also be useful to assess the 
transcription factors involved in photoreceptor development. 
Fig. 3. Retinal architecture in the human fetal retina and human iPSC retinal organoids. Immunohistochemistry pictures of WK11 (A-D) and WK18 (E-H) human fetal retina 
and DD30 (I-L) and D200 (M-P) LUMC0004iCTRL10 hiPSC-derived retinal organoids. Sections were stained with antibodies against: Ki67 (A, E, I, M), pH3 (A, E, I, M), 
p27kip1 (B, F), SOX9 (C, G, K, O), Recoverin (D, H, P), PAX6 (D, H), Islet 1/2 (J), PKCα (N), OTX2 (L). In human fetal retina at week 11 in the 1st trimester of pregnancy, 
we observed cycling cells that stained positive for anti-Ki67 and spanned the thickness of the neuroblast layer (NBL). The mitotic cells located most apically and stained positive 
for pH3 (A). Inner retinal cells as marked by p27kip1 and PAX6 were restricted to the ganglion cell layer and a subset of cells in the NBL (B and D). The cells that exited the cell 
cycle were marked with p27kip1, whereas the ganglion cells, amacrine cells, and migrating retinal progenitors were marked with PAX6. Radial glial progenitor cell nuclei 
spanned the thickness of the NBL and stained positive for anti-SOX9 (C). Newborn cone photoreceptors marked positive for anti-recoverin (D). In the human fetal retina at 
weeks 18 in the 2nd trimester of pregnancy, we observed the localisation of anti-pH3-positive mitotic cells most apically within the NBL (E). However, the cycling anti-Ki67- 
positive cells became mostly restricted to the middle NBL cells but also labeled occasional outer NBL cells (E). Both p27kip1-and PAX6-positive cells restricted to the inner NBL 
and the ganglion cell layer (F, H). SOX9-positive cell nuclei localised in the middle NBL and occasionally the outer NBL, marking maturing Müller glial cells (G). The outer NBL 
showed an increase in recoverin-positive photoreceptors at week 18 compared to week 11 (H). In early DD30 hiPSC retinal organoids we observed that Ki67-positive cycling cells 
spanned the thickness of the NBL with pH3-positive mitotic cells located most apically (I). Ki67-positive cycling cells were also detected in the ganglion cell layer (GCL). Islet1/2- 
positive cells were found mostly restricted to the GCL with sporadic cells in the NBL (J). SOX9-positive radial glial progenitor cell nuclei spanned the thickness of the NBL but 
were also seen occasionally in the GCL (K). Immature photoreceptors that stained positive for anti- OTX2 could be found in both the NBL and GCL (L). In later DD200 hiPSC- 
derived retinal organoids Ki67-positive cycling cells restricted mostly to the middle NBL but occasionally were detected in the outer NBL and in the GCL, whereas pH3-positive 
mitotic cells located apically (M). In the inner retina PKCα-positive bipolar cells (N) were detected. SOX9-positive cell nuclei became more restricted to the middle NBL but 
occasionally were detected in the outer NBL and the GCL (O). Recoverin-positive photoreceptor cells were mostly restricted to the outer NBL. Some recoverin-positive cells were 
detected within the NBL and occasional recoverin-positive cells were detected in the GCL (P). Scale bars: (A-P), 20 μm. Adapted from Quinn et al. 2019 [72] under a creative 
commons license. 
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Lastly, in addition to radial glial progenitors, a peripherally located 
stem cell-like niche called the ciliary marginal zone (CMZ) can 
contribute to the production of postmitotic cells to the retina in mam-
mals [76,86–88]. The Sasai laboratory used an induction reversal 
method to generate human ROs with RPE, which contained a CMZ at the 
boundary between these two tissues. This region contained CM-like stem 
cells, which were able to contribute to retinal expansion by de novo 
generation of retinal progenitors [89]. Further exploration of the 
mechanisms underlying CM-like stem cells will help advance ocular 
regenerative therapeutics. 
Retinal rganoids and disease modeling 
In recent years, retinal organoid models of various eye diseases have 
been created. These models can be either used for studying the under-
lying pathomechanisms as well as for therapeutic purposes. Table 1 
summarizes some RO models of retinal diseases that have been devel-
oped thus far. However, some questions are arising regarding the further 
applicability of organoid models for disease modeling. Points to consider 
include whether the developmental “age” of the ROs corresponds to 
when the patient would get disease onset typically, or whether the 
culturing microenvironment exacerbates disease characteristics in 
organoid culture are concerns that need to be addressed in the upcoming 
studies. Modeling of the late-stage disease will be a particular challenge 
due to the immaturity of ROs even after long-term cell culture, the 
addition of stressors to induce aging phenotypes should be explored. 
Furthermore, ROs are still relatively naive structures that lack optic 
nerve, retinal vasculature, and microglia. 
Applications of retinal organoids to drug studeis 
For drug studies, human RO technology promises to be a more 
realistic model of human development and disease than animal and 2- 
dimensional cell culture models [104,105]. RO models can be used to 
evaluate targeted therapy and drug toxicity in the pre-clinical drug 
development stage [106]. In what follows, we discuss two examples of 
RO-based drug studies. First, a model of advanced retinoblastoma tumor 
organoids (resembling retinal tumors and seeds) created by Saengwimol 
et al. was used to assess cell cycle arrest in response to drugs and their 
genotoxic effects. The model was used to compare the outcome of single 
drugs and their combinations. In the first step, they evaluated whether 
the result of this model will be comparable to clinical outcomes. Drugs 
commonly used in intravitreal chemotherapy, including melphalan, 
topotecan, and methotrexate were used with various concentrations and 
24–72(h) exposure times. Low dose melphalan (8 and 16 μM) with 
prolonged exposure time showed a similar effect to the high dose of 
melphalan (32 μM) with short exposure time, leading to induced S-phase 
arrest and reduced G2/M-phase. Topotecan (11 μM) efficiently reduced 
the number of tumor cells in G0/G1 and G2/M phases. Methotrexate 
showed the least anticancer effectiveness. Methotrexate reduced the 
G0/G1-phase cells and increased cell death in the sub-G1 phase, how-
ever, S and G2/M phases were activated. The results were comparable to 
clinical results indicating the translatability of RO data. As topotecan 
and melphalan showed similar effects, one may ask whether their 
combination will be a desired therapeutic strategy. Therefore, the re-
searchers took a second step to analyze targeted therapy and the geno-
toxicity of a combination of topotecan (11 μM) and melphalan (16 μM), 
which was challenging to perform in clinics. The combination not only 
had a profound influence on subretinal seeds or recurrent retinal tumors 
but also targeted proliferative tumor cones effectively [102]. However, a 
combination of melphalan and topotecan was more genotoxic than 
melphalan alone. This study thus shows the power of the RO model in 
addressing therapeutic challenges. 
In another study, Ito et al. used miPSC-derived ROs as a model for 
reproducing photoreceptor degeneration treated by 4-hydroxytamoxi-
fen (4-OHT) and diethylstilbestrol (DES) individually that induces 
acute cell death. Additionally, they established a fluorescent live-cell 
imaging system in order to evaluate their induced damage model. 
Those side effects were already confirmed in the mouse retinal explant 
experiment. Therefore, ROs can recapitulate the drug side effects. They 
also analyzed the protective effect of vitamin E (400 μM) and Lutein 
(200 nM) as ophthalmic supplements for treating the photoreceptor 
degeneration. The result showed the superior efficacy of vitamin E 
compared to Lutein in suppressing oxidative and endoplasmic reticulum 
(ER) stress-related gene [107]. Overall, ROs have been used in several 
proof-of-concept drug studies with promising results. Nevertheless, 
there are several shortcomings, such as the lack of vascularization and 
immune cells. Thus, current RO models cannot be used in drug studies 
such as screening of neuroprotective drug development for retinopathy, 
where incorporation of inflammatory cells is essential [105]. 
Applications retinal organoidsto transplantation therapy 
Pluripotent stem cells can be used to provide a potentially unlimited 
supply of retinal specific cell types. Retinal organoids derived from 
hESCs and hiPSCs can serve as a cellular source for transplantation 
purposes, either as a retinal cell suspension or an organized retinal sheet 
[108–111]. Most studies typically focus on the use of ROs as a source for 
rod and cone photoreceptors, but they have also been used as a source 
for retinal ganglion cells and Müller glial cells [62,109–113]. 
In 2016 a string of studies highlighted the need for reevaluation of 
previous photoreceptor donor transplantation studies due to cyto-
plasmic material transfer between donor and host cells [114–116]. 
These studies stressed that the propensity for transplanted donor pho-
toreceptors to integrate and provide functionality was more limited than 
initially thought, with many of the observed functional benefits likely 
coming from the donor-host transfer of phototransduction proteins 
[117,118]. The material transfer represents a novel therapeutic strategy 
for the rescue of diseased retinal cells [76,119]. However, for the eval-
uation of current photoreceptor transplantation experiments, the use of 
late-stage disease models in which the majority of photoreceptor cells 
are lost may be preferable for the assessment of cell integration and 
functional rescue. Nonetheless, the cell transplantation approach 
adopted, either cell suspension or cell sheet, may reflect the disease 
stage needing to be treated. In milder degenerative stages, donor cell 
suspensions may be advantageous. This is due to the preexisting archi-
tecture in which the donor cells can integrate into and support the 
remaining host photoreceptors. However, at later stages of degenera-
tion, where few or no photoreceptors remain, retinal sheets may be more 
optimal at surviving and forming synaptic connections with the 
remaining inner retina. 
Both photoreceptor cell suspensions and retinal sheets derived from 
ROs have been explored for the treatment of late-stage models of retinal 
disease in which nearly all host photoreceptors have already degen-
erated [62,108–110,120]. As an example, McLelland et al. used 
hESC-derived ROs as a source of healthy retinal tissue to rescue an 
immunodeficient late-stage retinal degenerative rat model. They found 
that the transplanted RO-derived retinal sheets went under differentia-
tion and integration, leading to an improvement in visual function, 
despite the degenerative microenvironment. Analysis of the trans-
planted retinal sheets showed the presence of rod and cone photore-
ceptors with putative outer segments, bipolar cells, Müller glial cells, 
amacrine cells, and horizontal cells, which were all derived from the 
transplant. The presence of increased immunoreactivity for synapto-
physin near the transplanted cells compared to areas further away from 
the transplant was suggestive of potential synaptic connectivity between 
the host and transplanted cells [109]. While the presence of transplanted 
maturated photoreceptors with potential synaptic connectivity is 
extremely promising, the evaluation of tangible functional rescue in 
degenerative models is still limited. As an example, the immunodeficient 
rat model used both by McLelland et al. and Tu et al. were found to still 
have light-responsive patches at 10 months of age, making it difficult to 
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Table 1 
Organoid models of retinal diseases.  
Disease Gene and mutation Organoid features 
LCA CEP290 [90,91]c.2991 + 1655A > G homozygous mutation [90] 
Two patients heterozygous for IVS26 + 1655A > G and c.5668G 
> T mutations. One patient homozygous for IVS26 and 1655A > G 
[91] 
Aberrant splicing, impaired ciliogenesis, reduced cilia incidence [90] 
Abnormal ciliogenesis, docked mother centriole were only observed in optic cups 
derived from CEP290 LCA patients [91] 
RPE65 [92] c.200T > G and c.430T > C All patient lines could generate well-layered ROs, which contained rods and cones 
that had inner segments and rudimentary outer segments. However, no 
photoreceptor phenotype was observed. In patient RPE cells, which were generated 
simultaneously with ROs, a significant decrease in RPE65 expression was found. No 
differences in biological function, as measured by POS phagocytosis and VEGF 
secretion, was found in patient iPSC derived RPE compared to control. 
AIPL1 [93] c.265 T > C homozygous mutation Despited a reduction in both AIPL1 and PDE6B being found in patient ROs no retinal 
degneration was detectable. Normal ultrastructural findings, expression of mature 
photoreceptor markers and similar gene expression profiles, except NEUROD6 a 
transcription factor involved in amacrine cell subtype specification, were found 
between control and AIPL1-LCA ROs. 
RP RPGR [94] 
c.1685_1686delAT, c.2234_2235delGA, c.2403_2404delAG 
mutations 
Significant defects in photoreceptors, including decreased photoreceptor cell 
number, cilia length, and expression of photoreceptor-related genes, were found 
between control and patient ROs. When the electrophysiological properties of 
patient rod-like cells were examnined compared to controls they were found to have 
a reduction in hyperpolarization-activated potassium current. This along with 
expression data highlighted a deficit in HCN channels. 
CRB1 [72] 
Patient 1: c.3122T > C homozygous; 
Patient 2: 
2983G > T and c.1892A > G; 
Patient 3: c.2843G > A and c.3122T > C 
Three hiPSC lines derived from CRB1 RP patients, when differentiated into ROs, 
showed a phenotype of disruptions at the outer limiting membrane (OLM), as 
demonstrated by ectopic photoreceptor nuclei above the OLM. The degenerative 
retinal phenotype of CRB1 RP patient hiPSC derived ROs was similar to that 
previously found in mice expressing variant CRB1C249W or lacking CRB1 [95,96]. 
USH2A [97] c.8559-2A > G 
and c.9127_9129delTCC 
Significant defects were identified from an early stage in patient compared to control 
ROs including delayed retinal self-organization, abnormal retinal neuroepithelium 
differentiation, and defective retinal progenitor cell development. A reduced 
diameter and thickness of the retinal neuroepithelium was found along with an 
increase in expression of apoptosis related genes in patient ROs. Additionally, a 
decrease in retinal cells including photoreceptors, Müller and amacrine cell were 
found in patient ROs. Other RO defects included aberrant basement membrane and 
tight junctions. Further gene ontology analysis identified differentially expressed 
gene enrinched for catagories involved in calcium signaling, retinal layer formation, 
dopaminergic synapse and vesical transport. 
Autosomal-dominant RP PRPF31 [98] 
Three related RP type 11 patients with c.1115_1125del11 
heterozygous mutation. 
One patient with severe RP with c.522_527 + 10 del heterozygous 
mutation. 
Progressive degenerative features were found in ROs with TEM showing patient 
photoreceptors had an increase in apoptotic nuclei and the presence of stress 
vacuoles compared with controls. Additionally, a significantly reduced reponse was 
found in patient ROs to the neurotransmitter GABA. Patient ROs also exhibited 
impared pre-mRNA slpicing and had an increase in differentially expressed genes in 
gene ontology catagories relating to the actin cytoskeleton, ciliary membrane, 
primary cilium, photoreceptor inner and outer segments, axon terminals and 
phototransduction. In accordance with this defective photoreceptor cilia were found 
in patient ROs. 
Late-onset RP PDE6B [65] c.694G > A homozygous mutation. Patient ROs before DD180 exhibited relatively normal retinal development as 
compared with controls. However, patient ROs at DD230 were found to have 
defective rod cell migration. Furthermore, gene ontology analysis found an 
enrichment of gene implicated in G-protein-coupled receptor activity, G-protein- 
coupled receptor signaling pathway and calcium ion binding in patient ROs. 
Additionally, an increase in cGMP levels were found in patient ROs, which may have 
led to the impaired formation of synaptic connections and the decrease in 




R120× nonsense mutation c.358C > T 
RP2 patient-derived ROs exhibit a spike in cell death in the ONL at DD150, with a 
subsequent thinning of the ONL detectable at DD180. The onset of cell death 
coincides with the timing of rod cell maturation and rhodopsin expression. In 
accordance with the thinning ONL, a reduction in the number of rhodopsin positive 
cells in the ONL was detected at DD180.    
Glaucoma OPTN [100] 
E50K missense mutation 
Early stages of retinal differentiation in ROs were unaffected by the OPTN (EK50) 
mutation. However, at later stages of maturation, retinal ganglion cells from derived 
from patient iPSCs exhibited neurite retraction, increased excitability, dysfunctional 
autophagy, as marked LC3 accumulation, and an increase in apoptosis of the inner 




Patient 1: c.625C > T 
Patient 2: c.488G > A 
Retinal splitting, outer-segment defects, abnormal paxillin turnover, defective 
retinoschisin production, impaired ER-Golgi transportation, defective 
photoreceptor connecting cilia, and altered expression of retinopathy-associated 
genes including IQCB1 and OPA1, which are associated with LCA and autosomal 
dominant optic atrophy, respectively).    
Retinoblastoma RB1 [103] 
RB1-null mutations [103] 
RB1 was found to be abundant in retinal progenitor cells and become downregulate 
during maturation of ROs. Loss of RB1, in RB1-null ROs, promoted S-phase entry, 
lead to an increase in apoptosis and caused a reduction in the number of 
photoreceptors, bipolar, and ganglion cells. However, loss of RB1 was not sufficient 
to induce retinoblastoma formation in ROs. 
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conclusively discriminate graft-originated responses from the remaining 
host activity [109,120]. This highlights the need for careful consider-
ation when choosing which degenerative models to use for such exper-
iments and also highlights the need to confirm functionality using 
numerous approaches. 
The CRISPR/Cas9, a technique has been used to correct mutations in 
patient iPSC lines leading to the amelioration, when differentiated, of 
the RO phenotype compared to ROs derived from the uncorrected pa-
tient line. This has been successfully studied on RO models of RP and 
XLRS [94,98,101]. Patient corrected stem cell could be utilized as a 
source for autologous cell transplantation for the treatment of retinal 
dystrophies. Lastly, during RO differentiation, there is a concomitant 
generation of RPE. Dissected RPE spheroids from ROs or RPE spheroids 
generated from the remaining cell culture after RO sorting can be used to 
generate RPE monolayers or could be dissected to form RPE sheets 
[121]. Transplantation of RPE is a promising strategy for treating 
advanced stages of eye disease such as RP, AMD, and Stargardt disease 
(STGD1) in which significant RPE loss is found [122–124]. 
Applications of retinal organoids to gene therapy 
Adeno-associated virus (AAV) is a small, nonenveloped, replication- 
deficient, single-stranded DNA parvovirus belonging to the genus 
Dependovirus. AAVs can be commandeered as a delivery vector for gene 
augmentation, currently the therapeutic strategy of choice for targeting 
hereditary retinal diseases [76,125]. Many studies have been performed 
using different promoter/serotype combinations to assess cell tropism 
and transduction efficiency of AAVs in ROs, with photoreceptors and 
radial glial progenitors/Müller glial cells being transduced [60,72,99, 
126–128]. Here, we provide two recent examples of AAV-mediated gene 
delivery in ROs. 
Lane et al. used AAV2/5 to deliver the RP2 gene to photoreceptors in 
an organoid model of X-linked retinitis pigmentosa (XLRP). RP2 patient- 
derived ROs exhibit a spike in cell death in the ONL at differentiation 
day (DD)150, with a subsequent thinning of the ONL detectable at 
DD180. The onset of cell death coincides with the timing of rod cell 
maturation and rhodopsin expression. In accordance with the thinning 
ONL, a reduction in the number of rhodopsin positive cells in the ONL 
was detected at DD180. After AAV2/5. CAGp.RP2 gene therapy, an 
amelioration of this degenerative phenotype was observed, as marked 
by a reduction in ONL thinning and restoration of rhodopsin expression 
[99]. This study highlights that the therapeutic potential of 
AAV-mediated delivery of RP2 should be further explored as a treatment 
for XLRP. 
The implementation of AAVs to deliver larger retinal genes is 
impeded by their limited cargo capacity of approximately 5 kb of DNA. 
Recently, Tornabene et al. used split inteins to mediate protein trans- 
splicing in human ROs. They found that multiple, AAV delivered, split 
intein-flanked polypeptides could be reconstituted to form large full- 
length proteins in mouse, pig, and human photoreceptors. Impor-
tantly, they were able to develop AAV-ABCA4 and AAV-CEP290 intein 
vectors to improve the retinal phenotype found in STGD1 and LCA type 
10 (LCA10) mouse models, respectively. Additionally, they were able to 
find expression of ABCA4 in STGD1 patient-derived ROs after adminis-
tration of AAV2/2-GRK1-ABCA4 intein vectors. 
Patient-derived ROs are a promising alternative to animal models for 
the testing of AAV-mediated gene augmentation strategies. However, 
the variability in AAV transduction efficiencies in ROs needs to be 
addressed [60,72,99,126–128]. Variations in transduction efficiencies 
may be due to the methodology used to generate ROs, promoter choice, 
viral titre, vector tropism, transgene detection method, timepoint of 
viral vector administration to RO, and the number of days 
post-administration before RO collection and analysis [99]. Particularly, 
the developmental timepoint specific bioavailability of receptors for 
AAV uptake may be a critical consideration for efficient transduction of 
RO cell types and therefore AAV vector choice [72,128]. Additionally, 
lentivirus is also capable of efficiently transducing photoreceptors in 
ROs and is an alternative delivery strategy to be further explored [85, 
106]. 
Retina chips 
Numerous physiological processes and disease progressions in the 
retina involve the presence of cells and structures from multiple devel-
opmental origins. For instance, blood vessels and immune cells, origi-
nating from outside the retinal lineage, play a critical role in the onset 
and progression of diabetic retinopathy and the wet form of age-related 
macular degeneration (wet-AMD) [129]. Retinal organoids as previ-
ously described can reflect a majority of the cell types and architecture 
of the retina, but cannot faithfully recreate several important 
disease-relevant structures such as the inner and outer blood-retina 
barriers (iBRB and oBRB). 
Organ chips are particularly well suited to model these tissue barriers 
since they enable a multilayered alignment of cells as well as a blood 
stream-like perfusion [130]. Thus, a prime application for retina-based 
chips is the modeling of the blood-retina-barriers (BRB), in particular, 
the outer BRB (oBRB), formed by retinal pigmented epithelial cells 
(RPE), and the adjacent choroidal microvascular network formed by 
microcapillary endothelial cells [131]. The simplest oBRB on-chip 
arrangement poses a two-channeled organ chip where RPE and endo-
thelial cells are seeded on opposite sides of a porous membrane. Sub-
sequent perfusion by a medium pump is then used to recreate a 
microvascular blood flow. 
In 2017, Chen et al. applied this concept using the RPE cell line 
ARPE19 and human umbilical vein endothelial cells (HUVEC) [132]. 
The chip was used to study the migration of HUVEC cells into the RPE 
compartment in normal, hypoxic, and hypoglycemic conditions. In all 
conditions, a decline of RPE cell number was observed, whereas the 
HUVEC cells migrated through the membrane towards the RPE layer. 
In the same year, Chung et al. presented a slightly different chip 
concept replacing the porous membrane by a fibrin hydrogel gap [133]. 
To mimic the three-dimensional choroidal vascular network, endothelial 
cells mixed with the fibrin gel were seeded in a channel below the fibrin 
gap. RPE (ARPE19) cells were seeded on the gel wall above in a separate 
chamber. Upon stimulation with the angiogenic growth factor VEGF, the 
choroidal endothelial cells infiltrated the fibrin gap and the RPE layer, 
recapitulating the pathogenic processes occurring in wet-AMD. Subse-
quent treatment with the anti-VEGF antibody bevacizumab, a widely 
used wet-AMD drug, could prevent the vessels spreading, emphasizing 
that blood-retina barrier chips can not only reproduce pathophysiolog-
ical processes but also reproduce therapeutic approaches. 
The next generation of chip systems was then aiming to not simply 
reproduce the outer barrier function of the retina but also to integrate 
the neural retina and the blood vessels barriers within the retina (iBRB). 
Following that idea, Yeste et al. used a multilayered chip design which 
was separated by several permeable membranes [134]. Besides the RPE 
(ARPE19) component, representing the oBRB and primary human 
retinal endothelial cells, representing the iBRB, they integrated a 
LCA, Leber congenital amaurosis; CEP290, centrosomal protein 29; RP, retinitis pigmentosa; VEGF, vascular endothelial growth factor; AIPL1, Aryl hydrocarbon 
receptor-interacting protein-like 1; OS, outer segment; RO, retinal organoid; RPE, retinal pigment epithelium; RPC, retinal progenitor cell; cGMP, Cyclic guanosine 
monophosphate; ONL, outer nuclear layer; GPR161, G-protein-coupled receptor; OLM, outer limiting membrane; GFAP, Glial fibrillary acidic protein; OPTN, opti-
neurin; NEUROD6, neuronal differentiation 6; PDE6B, Phosphodiesterase 6B; IQCB1, IQ Motif Containing B1; ERG, electroretinography; BM, basement membrane; 
HCN, hyperpolarization-activated cyclic nucleotide-gated; DD, differentiation day. 
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neuroblastoma cell line (SH-SY5Y), mimicking the neural part of the 
retina. Via the integration of a transepithelial electrical resistance 
measurement (TEER) system, they then validated the barrier function-
alities of the iBRB and oBRB. 
The retina chip introduced in 2019 by Achberger et al. aimed for 
modeling the oBRB together with the neural retina [135] (Fig. 4). By 
combining hiPSC-ROs with adherently cultured hiPSC-derived retinal 
pigment epithelium (RPE), they combined all major retinal cell types on 
one platform. The benefits of this chip were to have a sub-RPE choroi-
dal-like perfusion through the microfluidic channels of the chip, the 
recreate of the oBRB using iPSC-derived RPE and to connect the pho-
toreceptors (PRC) of the ROs with their direct neighbor cell type in vivo, 
the RPE. This close PRC-RPE proximity led to an increase of photore-
ceptor outer segment number after 7 days of co-culture as well as active 
phagocytosis of photoreceptor segments by the hiPSC- RPE. 
Applications of retina chips to drug studies 
As retina chips are able to mimic physiological processes and barriers 
in the retina, they are of high interest for the preclinical evaluation of 
drug effects [135,136]. In a proof-of-principle study, the retina chip 
from Achberger et al. was supplemented with chloroquine (anti-malaria 
drug) and gentamicin (antibiotic drug), which have both a detrimental 
effect on the retina. The retinopathic and toxic side effects observed in 
vivo could be reproduced, shown by staining cell death by propidium 
iodide (PI) and the lysosomal marker LAMP2. High doses of chloroquine 
(80 mg/ml) resulted in significant PI staining and an increase in LAMP2, 
reflecting the lysosomal dysfunction observed in vivo [137]. The toxicity 
of Gentamicin in the retina chip was dependent upon the presence of 
RPE. A decrease in toxicity was found in the presence of RPE indicating 
that these cells might act as a barrier that protects the retinal organoids 
from gentamicin toxicity. 
Retina chips have also been used to develop and test intraocular 
tamponades. Silicone oil (SO) is commonly used as intraocular tampo-
nade in different eye diseases such as retinal detachment and giant 
retinal tears [138,139]. Chan et al. analyzed the formation of SO 
droplets in a microfluidic chip designed with a retinal ganglion cell line 
to mimic the eye cavity [140]. In this study, the researchers could 
measure the size as well as the number of SO droplets and reproduced 
SO-aqueous interface. 
Applications of retina chips to cell (transplantation) therapy 
The efficiency of therapies to replace dysfunctional photoreceptors 
by RPCs is highly based on the migration of cells collectively and in the 
correct direction [141]. 
Mirsha et al. used a microfluidic model of the retina to study the 
effect of human and mouse eye geometries on retinal cell migration 
[142]. Using computational models and experiments, they found that a 
concentration gradient of stromal cell-derived factor 1 (SDF-1) was 
formed and played as a force for chemotaxis; in the high concentration 
of SDF-1, cells migrated toward higher concentrations of it while in low 
concentrations they did not move. Thakur et al. studied the adhesive and 
displacement dynamics of RPCs to check if the biomaterial used in 
transplantation can enhance and coordinate cell migrations [143]. 
Using a μLane, they found that cell-cell interactions are dominant when 
hyaluronic acid or laminin was used as a transplantation matrix while 
high cell-matrix interactions in fibronectin result in cell monolayer 
formation. These findings emphasize the importance of substrate nature 
in enhancing the efficiency of migration and consequently in the success 
of transplantation. The same concept was investigated further using 
Drosophila melanogaster as a model organism combined with micro-
fluidics by Pena et al. [144]. A novel electro-chemotactic study of the 
migratory behavior of RPCs was conducted by Mishra et al. [145]. By 
fabricating a galvano-microfluidic system, they were able to establish 
tunable superimposed electric fields to study its effects on cellular 
motility. Interestingly, they found that by using a combination of elec-
tric field and SDF-1 concentration gradient, not only the migration 
distance can be increased about three times, but also the directionality 
will be enhanced. By performing bioinformatics analysis, it was found 
that the reason was the down-regulation of adhesion proteins simulta-
neously with the up-regulation of cytoskeletal regulatory proteins. These 
studies pave the way for developing more advanced RC models to 
simulate post-transplantation remodeling. 
Fig. 4. The engineered retina chip model. (a) Image of the chip. Medium channels are colored with dyes for visualization. (b) A schematic concept of the retina chip. (c) A 3d 
reconstruction of a retinal organoid labeled by the photoreceptor surface marker PNA Lectin (red) and GFP-labeled hiPSC-derived RPE cells in the retina chip. Adapted from 
Achberger et al., 2019, CC BY 4.0 [135]. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) 
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Lens 
The initial steps for growing lens organoids or lentoid bodies (LBs) 
were made in the 1970s [146]. Three decades later, Yang and colleagues 
were the first to derive lens progenitor cells and LBs from hESCs [147]. 
They deployed a three-stage culturing system via sequential inhibition 
and activation of FGF, TGF-β, and Wnt signaling pathways. They could 
successfully culture a large number of LBs with this technique. Bone 
Morphogenetic Protein (BMP) signaling inhibition by noggin triggered 
cells towards neuroectodermal fate. Also, the role of FGF2 was found to 
be necessary for lentoid formation. Their model was limited in a few 
aspects. For example, terminal differentiation of the lens fibers was 
properly initiated but not completely executed, marked by the lower 
amounts of β- and ɣ-crystallins in LBs compared to the human lens but 
with comparable amounts in the initiation period. The LBs also tended to 
dissociate from their support from day 35 of culture. The use of 3D 
matrices containing laminin, collagen, and fibronectin, have allowed 
differentiation of LBs past day 35. Lacking light focusing ability was also 
one of the limitations of their model. Fu et al. used hiPSCs and induced 
them to lens progenitor cells and LBs by using a “fried egg” differenti-
ation method. The cells in this method have a fried egg appearance at a 
time during differentiation, with the yolk serving as E-cadherin+
differentiating cells (D-cells) which eventually form the LBs, and the egg 
white serving as E-cadherin− supporting cells (S cells) [148]. By using 
the same method of differentiation, they studied the autophagic activity 
in LBs derived from human iPSCs and ESCs. Their model can be used to 
investigate abnormalities in organelle degradation to form an organelle 
free zone (OFZ) during lens development [149]. Having an OFZ is 
crucial for the proper homeostasis of the lens, leading to cataract for-
mation if disrupted. LBs have been successfully derived from cataract 
patient iPSCs [150]. The LBs can be used for studying various causes of 
cataracts, including congenital cataracts and age-related cataracts (ARC) 
[151,152]. For modeling ARC, it has been found that LBs spontaneously 
become cloudy after a prolonged time in culture, which is accompanied 
by protein aggregation. The use of hydrogen peroxide accelerates this 
process. This model system may be a suitable ARC disease model for 
understanding the role of oxidative stress in cataractogenesis [152]. 
Murphy et al. developed an alternative differentiation methodology 
that generated LBs which contained minimal non-lens cells [153]. In 
contrast to the previous LB models, their model yielded more spherical 
mini-lenses with a biconvex appearance and with more light focusing 
ability. They could purify their cells by performing Magnetic-activated 
cell sorting (MACS) to select cells expressing receptor tyrosine 
kinase-like orphan receptor 1 (ROR1), acting as a potential lens 
epithelial cell (LEC) purification agent. Their system is ROR1+
micro-lens system. They also suggested that their model can be used to 
study posterior capsule opacification (PCO), which is considered the 
most common complication of cataract surgery. Their model can effec-
tively serve to understand the underlying mechanisms behind cataract 
risk factors, including age, diabetics, ultraviolet (UV) light, radiation, 
smoking, drug-induced, medications. The protein aggregates causing 
cataract or other particles causing light-scattering in the lens can be 
tested under high-throughput screening (HTS) conditions also for ther-
apeutic targets. Most of the transcriptomic profile is expressed in LBs. Ali 
et al. compared the LBs derived from hESCs and peripheral blood 
mononuclear cell (pBMc)-originated hiPSCs in terms of their tran-
scriptomic profile. They found that almost 70% of the total human 
protein-coding transcriptome is expressed in LBs. The hESCs and hiPSCs 
shared more than 96% in the similarity of transcriptome gene expres-
sion. However, they realized that the hiPSCs yield more differential gene 
expressions, including 416 down- and 291 up-regulated genes [154]. 
Discussion and conclusion 
Engineered organoids and organ chips will inevitability change the 
way we do in vitro eye research in the future. In particular, they provide 
us with the possibility to study individualized differences in disease 
manifestations [155]. Despite recent advances, there are some draw-
backs and challenges that need to be addressed [156]. Technical vari-
ability is a major issue in organoid systems, as such standardized 
protocols are needed to avoid inconsistencies between results reported 
by different laboratories. Similarly, the use of well-characterized 
commercially available pluripotent stem cell lines would aid in the 
interpretation of results between labs. Lack of vasculature is preventing 
the study of vascular diseases like diabetes and high-risk corneal 
transplantation. Another important issue is the difficulty of modeling 
interactions between different eye tissues. Organ chips may help in this 
regard; however, this in turn comes with its own shortcomings [157]. 
Cornea and retina chips are powerful in vitro tools to study drug effects, 
therapeutic approaches, and disease-relevant questions, but the current 
chips, however, are still minimalistic. Future developments could make 
these chips even more complex, reflecting, and recreating an increasing 
number of functional and anatomical cues of the human eye, which may 
undergo critical changes in aging and disease [158,159]. 
We expect that future use of organoids and organ chips will lead to a 
surge of new research directions. Viral diseases and microbiome analysis 
are two areas where such approaches may impact ophthalmology. It is 
often hard to model human viral diseases in animals due to the speci-
ficities of virus-host interactions. Organ chips and organoids have 
recently been introduced to the field of virology [160]. Over the past 
decades, a major advance in medicine has been the recognition of the 
critical role of the microbiome in health and disease. The organ chip 
technology provides a way to study direct interaction between the 
microbiome and the different kinds of tissues outside the human body. 
For example, the intestine chip model provided a discovery tool to study 
the diverse microbiome-related therapeutics [161]. The significance of 
the ocular microbiome for ocular surface diseases such as DED has 
recently been recognized [162]. In the future, ocular microbiome chip 
technology will expectedly emerge as a new concept and an interdisci-
plinary approach in the pathobiology and clinical management of ocular 
surface diseases and beyond [162]. 
Finally, the full potential of in vitro modeling will only be realized if 
relevant measurement approaches are developed to extract biochemical 
and physical data from the engineered models. Advances in omics 
technology, in particular, are crucial in this regard. For example, 
metabolomics has only recently been introduced to the field of ocular 
surface diseases [163]. Application of these techniques to the human eye 
and the engineered models require protocols that allow for handling 
small volumes and a small number of cells. Current research in analyt-
ical biosciences in parallel to the bio-inspired engineering methodology 
promises great potential for organoids and organ chips in clinical 
translational research. 
Lastly, organoids and organ chip technologies will allow for the 
testing of new therapeutic paradigms. For example, precision metab-
olome reprogramming was recently highlighted as a promising non- 
gene-specific therapeutic avenue for inherited retinal dystrophies 
which would be of interest to explore in a complex retina chip format 
which also contained microglia in addition to RPE and retina [164]. 
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A compartmentalized microfluidic chip with crisscross microgrooves and 
electrophysiological electrodes for modeling the blood-retinal barrier. Lab Chip 
2018. https://doi.org/10.1039/c7lc00795g. 
[135] Achberger K, Probst C, Haderspeck J, Bolz SS, Rogal J, Chuchuy J, et al. Merging 
organoid and organ-on-a-chip technology to generate complex multi-layer tissue 
models in a human retina-on-a-chip platform. Elife 2019;8:1–26. https://doi.org/ 
10.7554/elife.46188. 
[136] Peng Z, Zhou L, Wong JKW, Chan YK. Eye-on-a-chip (EOC) models and their role 
in the future of ophthalmic drug discovery. Expet Rev Ophthalmol 2020:1–3. 
https://doi.org/10.1080/17469899.2020.1788388. 00. 
[137] Chen PM, Gombart ZJ, Chen JW. Chloroquine treatment of ARPE-19 cells leads to 
lysosome dilation and intracellular lipid accumulation: possible implications of 
lysosomal dysfunction in macular degeneration. Cell Biosci 2011;1:1–10. https:// 
doi.org/10.1186/2045-3701-1-10. 
[138] Gonzalez MA, Flynn HW, Smiddy WE, Albini T, Berrocal AM, Tenzel P. Giant 
retinal tears after prior pars plana vitrectomy: management strategies and 
outcomes. Clin Ophthalmol 2013;7:20130826. https://doi.org/10.2147/OPTH. 
S48930. 
[139] Garnier S, Rahmi A, Grasswil C, Kodjikian L. Three hundred and sixty degree 
retinotomy for retinal detachments with severe proliferative vitreoretinopathy. 
Graefe’s Arch Clin Exp Ophthalmol 2013;251:2081–5. https://doi.org/10.1007/ 
s00417-013-2298-3. 
[140] Chan YK, Sy KHS, Wong CY, Man PK, Wong D, Shum HC. In vitro modeling of 
emulsification of silicone oil as intraocular tamponade using microengineered 
eye-on-a-chip. Investig Ophthalmol Vis Sci 2015;56:3314–9. https://doi.org/ 
10.1167/iovs.15-16728. 
[141] Norden C, Lecaudey V. Collective cell migration: general themes and new 
paradigms. Curr Opin Genet Dev 2019;57:54–60. https://doi.org/10.1016/j. 
gde.2019.06.013. 
[142] Mishra S, Thakur A, Redenti S, Vazquez M. A model microfluidics-based system 
for the human and mouse retina. Biomed Microdevices 2015;17. https://doi.org/ 
10.1007/s10544-015-0002-6. 
[143] Thakur A, Mishra S, Pena J, Zhou J, Redenti S, Majeska R, et al. Collective 
adhesion and displacement of retinal progenitor cells upon extracellular matrix 
substrates of transplantable biomaterials. J Tissue Eng 2018;9. https://doi.org/ 
10.1177/2041731417751286. 
[144] Pena, Zhang, Majeska Venkatesh, Vazquez. Invertebrate retinal progenitors as 
regenerative models in a microfluidic system. Cells 2019;8:1301. https://doi.org/ 
10.3390/cells8101301. 
[145] Mishra S, Peña JS, Redenti S, Vazquez M. A novel electro-chemotactic approach 
to impact the directional migration of transplantable retinal progenitor cells. Exp 
Eye Res 2019;185:107688. https://doi.org/10.1016/j.exer.2019.06.002. 
[146] Huang FL, Russell P, Kuwabara T. Fine structure of lentoid bodies derived from 
normal and cataractous mouse lenses. Exp Eye Res 1980;31:535–41. https://doi. 
org/10.1016/S0014-4835(80)80012-1. 
[147] Yang C, Yang Y, Brennan L, Bouhassira EE, Kantorow M, Cvekl A. Efficient 
generation of lens progenitor cells and lentoid bodies from human embryonic 
stem cells in chemically defined conditions. Faseb J 2010;24:3274–83. https:// 
doi.org/10.1096/fj.10-157255. 
N. Manafi et al.                                                                                                                                                                                                                                 
The Ocular Surface 19 (2021) 1–15
15
[148] Fu Q, Qin Z, Jin X, Zhang L, Chen Z, He J, et al. Generation of functional lentoid 
bodies from human induced pluripotent stem cells derived from urinary cells. 
Investig Ophthalmol Vis Sci 2017;58:517–27. https://doi.org/10.1167/iovs.16- 
20504. 
[149] Fu Q, Qin Z, Zhang L, Lyu D, Tang Q, Yin H, et al. A new long noncoding RNA ALB 
regulates autophagy by enhancing the transformation of LC3BI to LC3BII during 
human lens development. Mol Ther Nucleic Acids 2017;9:207–17. https://doi. 
org/10.1016/j.omtn.2017.09.011. 
[150] Qiu X, Yang J, Liu T, Jiang Y, Le Q, Lu Y. Efficient generation of lens progenitor 
cells from cataract patient-specific induced pluripotent stem cells. PloS One 2012; 
7. https://doi.org/10.1371/journal.pone.0032612. 
[151] Han C, Li J, Wang C, Ouyang H, Ding X, Liu Y, et al. Wnt5a contributes to the 
differentiation of human embryonic stem cells into lentoid bodies through the 
noncanonical Wnt/Jnk signaling pathway. Investig Ophthalmol Vis Sci 2018;59: 
3449–60. https://doi.org/10.1167/iovs.18-23902. 
[152] Qin Z, Zhang L, Lyu D, Li J, Tang Q, Yin H, et al. Opacification of lentoid bodies 
derived from human induced pluripotent stem cells is accelerated by hydrogen 
peroxide and involves protein aggregation. J Cell Physiol 2019;234:23750–62. 
https://doi.org/10.1002/jcp.28943. 
[153] Murphy P, Kabir MH, Srivastava T, Mason ME, Dewi CU, Lim S, et al. Light- 
focusing human micro-lenses generated from pluripotent stem cells model lens 
development and drug-induced cataract in vitro. Development 2018;145. https:// 
doi.org/10.1242/dev.155838. 
[154] Ali M, Kabir F, Thomson JJ, Ma Y, Qiu C, Delannoy M, et al. Comparative 
transcriptome analysis of hESC- and iPSC-derived lentoid bodies. Sci Rep 2019;9: 
1–9. https://doi.org/10.1038/s41598-019-54258-z. 
[155] Di Zazzo A, Lee S-M, Sung J, Niutta M, Coassin M, Mashaghi A, et al. Variable 
responses to corneal grafts: insights from immunology and systems biology. J Clin 
Med 2020. https://doi.org/10.3390/jcm9020586. 
[156] Kim J, Koo BK, Knoblich JA. Human organoids: model systems for human biology 
and medicine. Nat Rev Mol Cell Biol 2020. https://doi.org/10.1038/s41580-020- 
0259-3. 
[157] Junaid A, Mashaghi A, Hankemeier T, Vulto P. An end-user perspective on Organ- 
on-a-Chip: assays and usability aspects. Curr Opin Biomed Eng 2017. https://doi. 
org/10.1016/j.cobme.2017.02.002. 
[158] Mashaghi A, Hong J, Chauhan SK, Dana R. Ageing and ocular surface immunity. 
Br J Ophthalmol 2017. https://doi.org/10.1136/bjophthalmol-2015-307848. 
[159] Inomata T, Mashaghi A, Hong J, Nakao T, Dana R. Scaling and maintenance of 
corneal thickness during aging. PloS One 2017. https://doi.org/10.1371/journal. 
pone.0185694. 
[160] Tang H, Abouleila Y, Si L, Ortega-Prieto AM, Mummery CL, Ingber DE, et al. 
Human organs-on-chips for virology. Trends Microbiol 2020. https://doi.org/ 
10.1016/j.tim.2020.06.005. 
[161] Jalili-Firoozinezhad S, Gazzaniga FS, Calamari EL, Camacho DM, Fadel CW, 
Bein A, et al. A complex human gut microbiome cultured in an anaerobic 
intestine-on-a-chip. Nat Biomed Eng 2019. https://doi.org/10.1038/s41551-019- 
0397-0. 
[162] Heidari M, Noorizadeh F, Wu K, Inomata T, Mashaghi A. Dry eye disease: 
emerging approaches to disease analysis and therapy. J Clin Med 2019. https:// 
doi.org/10.3390/jcm8091439. 
[163] Di Zazzo A, Yang W, Coassin M, Micera A, Antonini M, Piccinni F, et al. Signaling 
lipids as diagnostic biomarkers for ocular surface cicatrizing conjunctivitis. J Mol 
Med 2020. https://doi.org/10.1007/s00109-020-01907-w. 
[164] Caruso S, Ryu J, Quinn PMJ, Tsang SH. Precision metabolome reprogramming for 
imprecision therapeutics in retinitis pigmentosa. J Clin Invest 2020. https://doi. 
org/10.1172/JCI139239. 
N. Manafi et al.                                                                                                                                                                                                                                 
